Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tummysoft
- Development stage
- Unknown
- Lead developer
- Tablets India
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Tummysoft is a line of probiotic and digestive enzyme supplements developed by Tablets India Limited to support gastrointestinal health and alleviate symptoms of digestive distress. The primary formulation, Tummysoft-AD, contains the probiotic strain *Bacillus coagulans* GBI-30, 6086 along with a comprehensive enzyme complex including alpha-amylase, lipase, papain, alpha-galactosidase, and lactase. These components work together to replenish beneficial gut flora and assist in the enzymatic hydrolysis of starches, lipids, proteins, complex sugars, and lactose. Tummysoft is indicated for the management of bloating, flatulence, indigestion, and infant colic, and is available in various oral formats such as tablets, mouth-melt sachets, drops, and dry syrups.
- Brand names
- TummysoftTummysoft-ADTummysoft DropsTummy Soft Dry Syrup
02
Targets
PEP (Pepsin)AMY (Pancreatic alpha-amylase)LCT (Lactase-phlorizin hydrolase)GehA (Triacylglycerol lipase GehA)
Beyond the preview
Go deeper on Tummysoft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tummysoft.